Matching samples

28_6w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743705
sample_title: 28_6w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 28; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 6w; diagnosis: UC

28_14w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743706
sample_title: 28_14w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 28; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 14w; diagnosis: UC

29_baseline_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743707
sample_title: 29_baseline_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 29; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: baseline; diagnosis: UC

29_2w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743708
sample_title: 29_2w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 29; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 2w; diagnosis: UC

29_6w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743709
sample_title: 29_6w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 29; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 6w; diagnosis: UC

29_14w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743710
sample_title: 29_14w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 29; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 14w; diagnosis: UC

23_6w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743711
sample_title: 23_6w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 23; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 6w; diagnosis: UC

13_2w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743712
sample_title: 13_2w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 13; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 2w; diagnosis: CD

23_14w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743713
sample_title: 23_14w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 23; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 14w; diagnosis: UC

13_6w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743714
sample_title: 13_6w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 13; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 6w; diagnosis: CD

24_baseline_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743715
sample_title: 24_baseline_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 24; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: baseline; diagnosis: UC

13_14w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743716
sample_title: 13_14w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 13; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 14w; diagnosis: CD

24_2w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743717
sample_title: 24_2w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 24; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 2w; diagnosis: UC

14_baseline_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Treatment control marker detected.

sample_accession: GSM5743718
sample_title: 14_baseline_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 14; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: baseline; diagnosis: CD

24_6w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743719
sample_title: 24_6w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 24; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 6w; diagnosis: UC

24_14w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743720
sample_title: 24_14w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 24; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 14w; diagnosis: UC

14_6w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743721
sample_title: 14_6w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 14; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 6w; diagnosis: CD

14_14w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743722
sample_title: 14_14w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 14; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 14w; diagnosis: CD

15_baseline_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743723
sample_title: 15_baseline_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 15; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: baseline; diagnosis: UC

12_baseline_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743724
sample_title: 12_baseline_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 12; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: baseline; diagnosis: UC

15_2w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743725
sample_title: 15_2w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 15; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 2w; diagnosis: UC

12_2w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743726
sample_title: 12_2w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 12; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 2w; diagnosis: UC

15_6w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743727
sample_title: 15_6w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 15; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 6w; diagnosis: UC

12_6w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743728
sample_title: 12_6w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 12; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 6w; diagnosis: UC

28_baseline_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743729
sample_title: 28_baseline_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 28; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: baseline; diagnosis: UC

23_baseline_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743730
sample_title: 23_baseline_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 23; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: baseline; diagnosis: UC

15_14w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743731
sample_title: 15_14w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 15; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 14w; diagnosis: UC

12_14w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743732
sample_title: 12_14w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 12; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 14w; diagnosis: UC

28_2w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743733
sample_title: 28_2w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 28; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 2w; diagnosis: UC

23_2w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743734
sample_title: 23_2w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 23; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 2w; diagnosis: UC

13_baseline_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Treatment control marker detected.

sample_accession: GSM5743735
sample_title: 13_baseline_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 13; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: baseline; diagnosis: CD

38_2w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743736
sample_title: 38_2w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 38; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 2w; diagnosis: CD

38_6w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743737
sample_title: 38_6w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 38; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 6w; diagnosis: CD

12_4h_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743738
sample_title: 12_4h_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 12; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 4h; diagnosis: UC

38_14w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743739
sample_title: 38_14w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 38; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 14w; diagnosis: CD

12_24h_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743740
sample_title: 12_24h_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 12; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 24h; diagnosis: UC

39_baseline_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743741
sample_title: 39_baseline_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 39; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: baseline; diagnosis: UC

12_72h_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743742
sample_title: 12_72h_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 12; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 72h; diagnosis: UC

39_2w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743743
sample_title: 39_2w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 39; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 2w; diagnosis: UC

13_4h_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743744
sample_title: 13_4h_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 13; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 4h; diagnosis: CD

43_baseline_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743745
sample_title: 43_baseline_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 43; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: baseline; diagnosis: UC

39_6w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743746
sample_title: 39_6w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 39; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 6w; diagnosis: UC

13_24h_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743747
sample_title: 13_24h_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 13; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 24h; diagnosis: CD

43_2w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743748
sample_title: 43_2w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 43; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 2w; diagnosis: UC

23_4h_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743749
sample_title: 23_4h_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 23; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 4h; diagnosis: UC

39_14w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743750
sample_title: 39_14w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 39; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 14w; diagnosis: UC

13_72h_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743751
sample_title: 13_72h_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 13; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 72h; diagnosis: CD

43_6w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743752
sample_title: 43_6w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 43; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 6w; diagnosis: UC

23_24h_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743753
sample_title: 23_24h_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 23; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 24h; diagnosis: UC

40_baseline_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Treatment control marker detected.

sample_accession: GSM5743754
sample_title: 40_baseline_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 40; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: baseline; diagnosis: CD

14_4h_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743755
sample_title: 14_4h_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 14; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 4h; diagnosis: CD

43_14w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743756
sample_title: 43_14w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 43; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 14w; diagnosis: UC

23_72h_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743757
sample_title: 23_72h_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 23; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 72h; diagnosis: UC

40_2w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743758
sample_title: 40_2w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 40; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 2w; diagnosis: CD

14_24h_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743759
sample_title: 14_24h_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 14; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 24h; diagnosis: CD

44_baseline_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743760
sample_title: 44_baseline_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 44; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: baseline; diagnosis: UC

40_14w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743761
sample_title: 40_14w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 40; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 14w; diagnosis: CD

44_6w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743762
sample_title: 44_6w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 44; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 6w; diagnosis: UC

44_14w_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743763
sample_title: 44_14w_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 44; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 14w; diagnosis: UC

29_4h_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743764
sample_title: 29_4h_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 29; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 4h; diagnosis: UC

38_baseline_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Treatment control marker detected.

sample_accession: GSM5743765
sample_title: 38_baseline_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 38; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: baseline; diagnosis: CD

29_24h_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743766
sample_title: 29_24h_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 29; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 24h; diagnosis: UC

29_72h_IFX_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743767
sample_title: 29_72h_IFX_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 29; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Non-remission; time point: 72h; diagnosis: UC

14_2w_IFX_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743768
sample_title: 14_2w_IFX_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 14; cohort: Discovery - Infliximab; treatment: Infliximab; remission at week 14: Remission; time point: 2w; diagnosis: CD

3_baseline_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Treatment control marker detected.

sample_accession: GSM5743769
sample_title: 3_baseline_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 3; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: baseline; diagnosis: CD

5_6w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743770
sample_title: 5_6w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 5; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 6w; diagnosis: UC

3_2w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743771
sample_title: 3_2w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 3; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 2w; diagnosis: CD

5_14w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743772
sample_title: 5_14w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 5; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 14w; diagnosis: UC

3_6w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743773
sample_title: 3_6w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 3; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 6w; diagnosis: CD

7_baseline_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Treatment control marker detected.

sample_accession: GSM5743774
sample_title: 7_baseline_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 7; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: baseline; diagnosis: CD

3_14w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743775
sample_title: 3_14w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 3; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 14w; diagnosis: CD

7_2w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743776
sample_title: 7_2w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 7; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 2w; diagnosis: CD

4_baseline_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743777
sample_title: 4_baseline_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 4; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: baseline; diagnosis: UC

7_6w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743778
sample_title: 7_6w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 7; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 6w; diagnosis: CD

4_2w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743779
sample_title: 4_2w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 4; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 2w; diagnosis: UC

7_14w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743780
sample_title: 7_14w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 7; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 14w; diagnosis: CD

4_6w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743781
sample_title: 4_6w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 4; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 6w; diagnosis: UC

8_baseline_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743782
sample_title: 8_baseline_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 8; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: baseline; diagnosis: UC

4_14w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743783
sample_title: 4_14w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 4; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 14w; diagnosis: UC

8_2w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743784
sample_title: 8_2w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 8; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 2w; diagnosis: UC

5_baseline_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743785
sample_title: 5_baseline_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 5; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: baseline; diagnosis: UC

8_6w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743786
sample_title: 8_6w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 8; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 6w; diagnosis: UC

5_4h_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743787
sample_title: 5_4h_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 5; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 4h; diagnosis: UC

8_14w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743788
sample_title: 8_14w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 8; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 14w; diagnosis: UC

5_24h_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743789
sample_title: 5_24h_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 5; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 24h; diagnosis: UC

5_2w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743790
sample_title: 5_2w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 5; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 2w; diagnosis: UC

41_24h_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743791
sample_title: 41_24h_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 41; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 24h; diagnosis: CD

20_6w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743792
sample_title: 20_6w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 20; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 6w; diagnosis: UC

20_14w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743793
sample_title: 20_14w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 20; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 14w; diagnosis: UC

25_2w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743794
sample_title: 25_2w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 25; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 2w; diagnosis: CD

22_baseline_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743795
sample_title: 22_baseline_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 22; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: baseline; diagnosis: UC

25_6w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743796
sample_title: 25_6w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 25; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 6w; diagnosis: CD

22_2w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743797
sample_title: 22_2w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 22; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 2w; diagnosis: UC

25_14w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743798
sample_title: 25_14w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 25; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 14w; diagnosis: CD

46_baseline_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743799
sample_title: 46_baseline_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 46; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: baseline; diagnosis: UC

22_6w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743800
sample_title: 22_6w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 22; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 6w; diagnosis: UC

26_baseline_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Treatment control marker detected.

sample_accession: GSM5743801
sample_title: 26_baseline_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 26; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: baseline; diagnosis: CD

46_2w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743802
sample_title: 46_2w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 46; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 2w; diagnosis: UC

19_baseline_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Treatment control marker detected.

sample_accession: GSM5743803
sample_title: 19_baseline_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 19; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: baseline; diagnosis: CD

22_14w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743804
sample_title: 22_14w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 22; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 14w; diagnosis: UC

26_4h_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743805
sample_title: 26_4h_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 26; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 4h; diagnosis: CD

19_2w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743806
sample_title: 19_2w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 19; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 2w; diagnosis: CD

26_24h_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743807
sample_title: 26_24h_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 26; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 24h; diagnosis: CD

46_14w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743808
sample_title: 46_14w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 46; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 14w; diagnosis: UC

19_6w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743809
sample_title: 19_6w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 19; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 6w; diagnosis: CD

19_14w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743810
sample_title: 19_14w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 19; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 14w; diagnosis: CD

26_2w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743811
sample_title: 26_2w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 26; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 2w; diagnosis: CD

37_baseline_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743812
sample_title: 37_baseline_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 37; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: baseline; diagnosis: UC

20_baseline_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743813
sample_title: 20_baseline_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 20; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: baseline; diagnosis: UC

25_baseline_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Treatment control marker detected.

sample_accession: GSM5743814
sample_title: 25_baseline_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 25; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: baseline; diagnosis: CD

26_6w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743815
sample_title: 26_6w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 26; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 6w; diagnosis: CD

37_2w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743816
sample_title: 37_2w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 37; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 2w; diagnosis: UC

25_4h_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743817
sample_title: 25_4h_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 25; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 4h; diagnosis: CD

41_baseline_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Treatment control marker detected.

sample_accession: GSM5743818
sample_title: 41_baseline_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 41; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: baseline; diagnosis: CD

26_14w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743819
sample_title: 26_14w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 26; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 14w; diagnosis: CD

37_6w_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743820
sample_title: 37_6w_VDZ_NR_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 37; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Non-remission; time point: 6w; diagnosis: UC

20_2w_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. organism: Homo sapiens — Insufficient evidence. assay type: bulk RNA-seq — Insufficient evidence. specimen category: Tissue or biopsy — Insufficient evidence. Study role: Case marker detected.

sample_accession: GSM5743821
sample_title: 20_2w_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 20; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 2w; diagnosis: UC

25_24h_VDZ_R_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.

sample_accession: GSM5743822
sample_title: 25_24h_VDZ_R_RNA
source_name: Peripheral Whole-Blood
characteristics: patient: 25; cohort: Discovery - Vedolizumab; treatment: Vedolizumab; remission at week 14: Remission; time point: 24h; diagnosis: CD

41_4h_VDZ_NR_RNA

Not included: the study role or selected requirements have incomplete or conflicting evidence. Case: organism: Homo sapiens — Insufficient evidence. Case: assay type: bulk RNA-seq — Insufficient evidence. Case: specimen category: Tissue or biopsy — Insufficient evidence. Control: organism: Homo sapiens — Insufficient evidence. Control: assay type: bulk RNA-seq — Insufficient evidence. Control: specimen category: Tissue or biopsy — Insufficient evidence. Study role: No explicit case or control marker detected.